{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:43:23Z","timestamp":1771919003483,"version":"3.50.1"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,4,11]],"date-time":"2021-04-11T00:00:00Z","timestamp":1618099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Diabetic foot infections (DFIs) represent a serious threat to public health because of their frequency and the severity of their consequences, i.e. osteomyelitis and amputation. The management of diabetic foot osteomyelitis (DFOM) requires prolonged antibiotic therapy. In Western countries, Gram-positive bacteria are the most commonly encountered pathogens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>This study evaluated the in vitro activity of dalbavancin, a novel lipoglycopeptide with extended half-life, recently marketed in Europe for acute bacterial skin and skin structure infections, on a panel of Gram-positive bacteria responsible for DFOM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Dalbavancin activity was evaluated against a panel of Gram-positive bacterial strains isolated from bone biopsies performed by a trained surgeon among patients with suspected DFOM. MICs were determined using MIC Test Strips (Liofilchem) and confirmed with the EUCAST broth microdilution method. Three other antimicrobial agents (vancomycin, teicoplanin and ceftobiprole) were used as comparators.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Dalbavancin showed excellent activity against all Gram-positive bacterial strains tested, including one teicoplanin-resistant Staphylococcus epidermidis isolate. With MIC50 and MIC90 values of 0.047 and 0.094\u2009mg\/L, respectively, dalbavancin showed the most potent in vitro activity among antimicrobial agents tested.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>With its efficacy, good tolerability and unique pharmacokinetic properties, dalbavancin appears to be a promising treatment for DFOM involving Gram-positive bacteria.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkab117","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T12:09:18Z","timestamp":1616846958000},"page":"2057-2060","source":"Crossref","is-referenced-by-count":7,"title":["<i>In vitro<\/i>activity of dalbavancin against Gram-positive bacteria isolated from diabetic foot osteomyelitis"],"prefix":"10.1093","volume":"76","author":[{"given":"Alix","family":"Pantel","sequence":"first","affiliation":[{"name":"Virulence Bact\u00e9rienne et Infections Chroniques, INSERM U1047, Universit\u00e9 de Montpellier, Service de Microbiologie et Hygi\u00e8ne Hospitali\u00e8re, Clinique du Pied Diab\u00e9tique Gard Occitanie, CHU N\u00eemes, N\u00eemes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oriane","family":"Nachar","sequence":"additional","affiliation":[{"name":"Service de Microbiologie et Hygi\u00e8ne Hospitali\u00e8re, CHU N\u00eemes, N\u00eemes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agathe","family":"Boudet","sequence":"additional","affiliation":[{"name":"Virulence Bact\u00e9rienne et Infections Chroniques, INSERM U1047, Universit\u00e9 de Montpellier, Service de Microbiologie et Hygi\u00e8ne Hospitali\u00e8re, Clinique du Pied Diab\u00e9tique Gard Occitanie, CHU N\u00eemes, N\u00eemes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Loubet","sequence":"additional","affiliation":[{"name":"Virulence Bact\u00e9rienne et Infections Chroniques, INSERM U1047, Universit\u00e9 de Montpellier, Service des Maladies Infectieuses et Tropicales, Clinique du Pied Diab\u00e9tique Gard Occitanie, CHU Car\u00e9meau, N\u00eemes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Schuldiner","sequence":"additional","affiliation":[{"name":"Virulence Bact\u00e9rienne et Infections Chroniques, INSERM U1047, Universit\u00e9 de Montpellier, Service des Maladies M\u00e9taboliques et Endocriniennes, Clinique du Pied Diab\u00e9tique Gard Occitanie, CHU Car\u00e9meau, N\u00eemes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Cellier","sequence":"additional","affiliation":[{"name":"Service de Chirurgie Orthop\u00e9dique, Clinique du Pied Diab\u00e9tique Gard Occitanie, CHU Car\u00e9meau, N\u00eemes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Sotto","sequence":"additional","affiliation":[{"name":"Virulence Bact\u00e9rienne et Infections Chroniques, INSERM U1047, Universit\u00e9 de Montpellier, Service des Maladies Infectieuses et Tropicales, Clinique du Pied Diab\u00e9tique Gard Occitanie, CHU Car\u00e9meau, N\u00eemes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Dunyach-Remy","sequence":"additional","affiliation":[{"name":"Virulence Bact\u00e9rienne et Infections Chroniques, INSERM U1047, Universit\u00e9 de Montpellier, Service de Microbiologie et Hygi\u00e8ne Hospitali\u00e8re, Clinique du Pied Diab\u00e9tique Gard Occitanie, CHU N\u00eemes, N\u00eemes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9484-0304","authenticated-orcid":false,"given":"Jean-Philippe","family":"Lavigne","sequence":"additional","affiliation":[{"name":"Virulence Bact\u00e9rienne et Infections Chroniques, INSERM U1047, Universit\u00e9 de Montpellier, Service de Microbiologie et Hygi\u00e8ne Hospitali\u00e8re, Clinique du Pied Diab\u00e9tique Gard Occitanie, CHU N\u00eemes, N\u00eemes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,4,11]]},"reference":[{"key":"2021071609140746000_dkab117-B1","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1056\/NEJMra1615439","article-title":"Diabetic foot ulcers and their recurrence","volume":"376","author":"Armstrong","year":"2017","journal-title":"N Engl J Med"},{"key":"2021071609140746000_dkab117-B2","doi-asserted-by":"crossref","first-page":"e3250.","DOI":"10.1002\/dmrr.3250","article-title":"Diagnosing diabetic foot osteomyelitis","volume":"36 Suppl 1","author":"Senneville","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"2021071609140746000_dkab117-B3","doi-asserted-by":"crossref","first-page":"e3280.","DOI":"10.1002\/dmrr.3280","article-title":"Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update)","volume":"36 Suppl 1","author":"Lipsky","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"2021071609140746000_dkab117-B4","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2337\/db12-0771","article-title":"The neuropathic diabetic foot ulcer microbiome is associated with clinical factors","volume":"62","author":"Gardner","year":"2013","journal-title":"Diabetes"},{"key":"2021071609140746000_dkab117-B5","doi-asserted-by":"crossref","first-page":"209.","DOI":"10.3390\/toxins8070209","article-title":"Staphylococcus aureus toxins and diabetic foot ulcers: role in pathogenesis and interest in diagnosis","volume":"8","author":"Dunyach-Remy","year":"2016","journal-title":"Toxins (Basel)"},{"key":"2021071609140746000_dkab117-B6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40121-015-0077-7","article-title":"Dalbavancin: a novel lipoglycopeptide antibiotic with extended activity against Gram-positive infections","volume":"4","author":"Smith","year":"2015","journal-title":"Infect Dis Ther"},{"key":"2021071609140746000_dkab117-B7","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijid.2019.02.005","article-title":"Antibiotic penetration into bone and joints: an updated review","volume":"81","author":"Thabit","year":"2019","journal-title":"Int J Infect Dis"},{"key":"2021071609140746000_dkab117-B8","doi-asserted-by":"crossref","first-page":"ofy331.","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety","volume":"6","author":"Rappo","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2021071609140746000_dkab117-B9","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ijantimicag.2019.08.006","article-title":"French national cohort of first use of dalbavancin: a high proportion of off-label use","volume":"54","author":"Dinh","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2021071609140746000_dkab117-B10","doi-asserted-by":"crossref","first-page":"e02280","DOI":"10.1128\/AAC.02280-18","article-title":"Safety and efficacy of prolonged use of dalbavancin in bone and joint infections","volume":"63","author":"Morata","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021071609140746000_dkab117-B11","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1128\/AAC.00286-06","article-title":"In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic Gram-positive isolates recovered from diabetic foot infections","volume":"50","author":"Goldstein","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2021071609140746000_dkab117-B12","doi-asserted-by":"crossref","first-page":"O1052","DOI":"10.1111\/1469-0691.12743","article-title":"Staphylococcus caprae bone and joint infections: a re-emerging infection?","volume":"20","author":"Seng","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2021071609140746000_dkab117-B13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijid.2018.11.011","article-title":"In vitro activity of tedizolid and dalbavancin against MRSA strains is dependent on infection source","volume":"78","author":"Azrad","year":"2019","journal-title":"Int J Infect Dis"},{"key":"2021071609140746000_dkab117-B14","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ijantimicag.2017.12.011","article-title":"Dalbavancin in vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011\u20132016)","volume":"51","author":"Pfaller","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2021071609140746000_dkab117-B15","doi-asserted-by":"crossref","first-page":"a026989.","DOI":"10.1101\/cshperspect.a026989","article-title":"Approved glycopeptide antibacterial drugs: mechanism of action and resistance","volume":"6","author":"Zeng","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2021071609140746000_dkab117-B16","doi-asserted-by":"crossref","first-page":"1580.","DOI":"10.3390\/microorganisms8101580","article-title":"Biofilms in diabetic foot ulcers: significance and clinical relevance","volume":"8","author":"Pouget","year":"2020","journal-title":"Microorganisms"},{"key":"2021071609140746000_dkab117-B17","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3389\/fmicb.2020.00553","article-title":"Effect of dalbavancin on staphylococcal biofilms when administered alone or in combination with biofilm-detaching compounds","volume":"11:","author":"\u017diemyt\u0117","year":"2020","journal-title":"Front Microbiol"},{"key":"2021071609140746000_dkab117-B18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.diagmicrobio.2017.09.015","article-title":"Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococci","volume":"90","author":"Neudorfer","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021071609140746000_dkab117-B19","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1093\/jac\/dkaa163","article-title":"Efficacy of dalbavancin against MRSA biofilms in a rat model of orthopaedic implant-associated infection","volume":"75","author":"Silva","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2021071609140746000_dkab117-B20","doi-asserted-by":"crossref","first-page":"243","DOI":"10.5455\/medarh.2020.74.243-245","article-title":"Successful treatment of diabetic foot osteomyelitis with dalbavancin","volume":"74","author":"Loupa","year":"2020","journal-title":"Med Arch"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/8\/2057\/39065383\/dkab117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/8\/2057\/39065383\/dkab117.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T05:43:16Z","timestamp":1698126196000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/8\/2057\/6220393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,11]]},"references-count":20,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,4,11]]},"published-print":{"date-parts":[[2021,7,15]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab117","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8,1]]},"published":{"date-parts":[[2021,4,11]]}}}